Remedium Lifecare Strengthens Leadership for Next-Phase Growth
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd, a BSE-listed pharmaceutical and specialty chemicals company, has announced two new board appointments as part of its next-phase growth strategy. Mr. Vignesh Laxman Gawde has been appointed as Whole-Time Director, bringing over 14 years of experience in pharmaceutical R&D and analytical development from companies like Ajanta Pharma, Inventia Healthcare, and Elder Pharmaceuticals. Mr. Rambhajan Vishwakarma has been appointed as Independent Director, with over 15 years of experience in banking and financial services from HDFC Bank, ICICI Bank, and other financial institutions. The company stated that these appointments aim to strengthen R&D capabilities, quality assurance, corporate governance, and financial oversight. Managing Director Adarsh Munjal said the new leaders will help drive innovation, operational excellence, and shareholder value.
These appointments signal Remedium Lifecare's intent to scale up its pharmaceutical R&D and governance framework. For shareholders, this is a neutral-to-positive development — it strengthens the leadership bench in core operational and financial areas, though actual business impact will depend on execution of the stated growth plans.